scholarly article | Q13442814 |
P356 | DOI | 10.1177/0004867412464717 |
P698 | PubMed publication ID | 23093053 |
P50 | author | Michael Berk | Q30504747 |
P2093 | author name string | João Data-Franco | |
P2860 | cites work | The amplification of somatic symptoms | Q28292452 |
No gender differences in placebo responses of patients with major depressive disorder | Q31871526 | ||
Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer | Q33625012 | ||
The subjective experience of pain: where expectations become reality | Q33943765 | ||
Nocebo-induced hyperalgesia during local anesthetic injection. | Q34020725 | ||
Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group | Q34067329 | ||
Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches | Q34158126 | ||
Influence of context effects on health outcomes: a systematic review. | Q34186909 | ||
How the number of learning trials affects placebo and nocebo responses | Q34204013 | ||
Presenting risk information--a review of the effects of "framing" and other manipulations on patient outcomes. | Q34228750 | ||
Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo | Q34273139 | ||
Influence of the behaviour pattern on the nocebo response of healthy volunteers | Q34346886 | ||
Overt versus covert treatment for pain, anxiety, and Parkinson's disease | Q34359487 | ||
Nonspecific medication side effects and the nocebo phenomenon | Q34519096 | ||
The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. | Q34581978 | ||
Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses | Q34746177 | ||
A collaborative approach to the treatment alliance in bipolar disorder | Q35947326 | ||
Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects | Q36375840 | ||
A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect | Q37113699 | ||
A systematic review of adverse events in placebo groups of anti-migraine clinical trials | Q37603565 | ||
Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis | Q37610143 | ||
Enhancing medication adherence in patients with bipolar disorder | Q37664710 | ||
Patient expectancy and post-chemotherapy nausea: a meta-analysis | Q37729921 | ||
Nocebo in fibromyalgia: meta‐analysis of placebo‐controlled clinical trials and implications for practice | Q37942656 | ||
Social Psychologic Factors Affecting the Presentation of Bodily Complaints | Q39914445 | ||
Further evidence for individual differences in placebo responding: an interactionist perspective | Q40218163 | ||
Placebo/nocebo symptom reporting in a sham herbal supplement trial | Q40270432 | ||
The Nocebo Phenomenon: Concept, Evidence, and Implications for Public Health | Q41609492 | ||
A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. | Q43662938 | ||
Placebo and Nocebo Responses, Cortisol, and Circulating Beta-Endorphin | Q44595395 | ||
Nocebo effects in multiple sclerosis trials: a meta-analysis | Q46822234 | ||
Increased response to a putative panicogenic nocebo administration in female patients with panic disorder | Q49052685 | ||
Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? | Q50148458 | ||
Nonspecific side effects of oral contraceptives: nocebo or noise? | Q50654952 | ||
Reconsidering the role of personality in placebo effects: dispositional optimism, situational expectations, and the placebo response | Q50972827 | ||
Headaches and the nocebo effect | Q51014201 | ||
Gender and the nocebo response following conditioning and expectancy | Q51649240 | ||
Women encounter ADRs more often than do men. | Q51695259 | ||
Somatization in the population: from mild bodily misperceptions to disabling symptoms | Q51798700 | ||
Alternate methods of framing information about medication side effects: incremental risk versus total risk of occurrence | Q51893433 | ||
The role of learning in nocebo and placebo effects | Q51960960 | ||
An experimental analysis of classically conditioned nausea during cancer chemotherapy | Q52229404 | ||
Psychological factors associated with severe abuse of the Hemodialysis diet | Q52293429 | ||
Why medication in involuntary treatment may be less effective: The placebo/nocebo effect | Q57821117 | ||
The impact of personality on the reporting of unfounded symptoms and illness | Q58274274 | ||
P433 | issue | 7 | |
P921 | main subject | nocebo | Q1332954 |
P304 | page(s) | 617-623 | |
P577 | publication date | 2012-10-23 | |
P1433 | published in | Australian and New Zealand Journal of Psychiatry | Q4824838 |
P1476 | title | The nocebo effect: a clinicians guide | |
P478 | volume | 47 |
Q36274662 | Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools |
Q38129457 | Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome. |
Q37137286 | Changes in perception of treatment efficacy are associated to the magnitude of the nocebo effect and to personality traits. |
Q38363609 | Nocebo and the potential harm of 'high risk' labelling: a scoping review |
Q30596803 | Nocebo effect in randomized clinical trials of antidepressants in children and adolescents: systematic review and meta-analysis. |
Q90264124 | Pain Anticipation and Nocebo-Related Responses: A Descriptive Mini-Review of Functional Neuroimaging Studies in Normal Subjects and Precious Hints on Pain Processing in the Context of Neurodegenerative Disorders |
Q64062792 | Statins and Inflammation: New Therapeutic Opportunities in Psychiatry |
Q92069839 | The Clinical Implications of Nocebo Effects for Biosimilar Therapy |
Q92799625 | The Other Side of the Coin: Nocebo Effects and Psychotherapy |
Q36719631 | The nocebo effect of drugs |
Q47586296 | The role of depression pharmacogenetic decision support tools in shared decision making. |
Q47106974 | Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect |
Search more.